

REMARKS

This response revises the claims of this application. Accordingly, a detailed listing is presented, with appropriately defined status identifiers, for all claims that are or were in the application, irrespective of what claims remain under examination. Upon entry of the response, claims 2, 6-47, 49, 54-55, 60-61 & 66-67 will be pending.

Applicants elect Group 1, claims 1—47, 49, 54, 55, 60 and 61, drawn to an antibody. Applicant further elects "species 2," identified in the action by virtue of "activity of inhibiting the coaggregation of *P. gingivalis* and activity of promoting human neutrophilic phagocytosis."

Finally, the Commissioner is authorized to charge any additional fees, which may be required under 37 CFR §§ 1.16-1.17, and to credit any overpayment to Deposit Account No. 19-0741. Should no proper payment accompany this response, then the Commissioner is authorized to charge the unpaid amount to the same deposit account. If any extension is needed for timely acceptance of submitted papers, Applicants petition for such extension under 37 CFR §1.136 and authorize payment of relevant fees from the deposit account.

Respectfully submitted,

Date 15 January 2008

By S. A. Bent

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768